Covid-19
COVID-19
may elevate the risk of hyperglycemia and other complications in patients with
and without prior diabetes history. Individuals
with preexisting diabetes show higher incidence of COVID-19 illness and poorer
prognosis upon infection. Likewise, an increased frequency of diabetes onset
and diabetes complications has been reported in patie...
Booster interval and age updatedThe U.S. Food and Drug
Administration (FDA) and CDC authorizing the use of a Pfizer-BioNTech & Moderna COVID-19 Vaccine to shorten the time
between the completion of a primary series of the 2 vaccines and a booster dose
to at least 5 months after completion of the primary vaccination series for
individuals 12 yea...
TAKE-HOME MESSAGE
Patients who are hospitalized with COVID-19 have
been shown to have a high risk of thromboembolic events post discharge. In
this open-label randomized trial, the authors showed that, in high-risk
patients who are hospitalized for COVID-19, the use of thromboprophylaxis
and rivaroxaban for 35 days after di...
SummaryWhat is already known about
this topic?Pregnant women with COVID-19 are
at increased risk for severe illness and adverse birth outcomes, yet many
remain reluctant to be vaccinated.What is added by this report?In a retrospective cohort of
>40,000 pregnant women, COVID-19 vaccination during pregnancy was not
associated with preterm bir...
The World Health Organization announced
Friday it has designated the newly identified coronavirus variant, B.1.1.529,
as a variant of concern, named Omicron.The new Omicron variant was first
reported to the WHO from South Africa on 24 November, 2021. It has also been
identified in Botswana, Belgium, Hong Kong and Israel. It appears to be spread...
The U.S. Food and Drug
Administration revised the emergency use authorization (EUA) of bamlanivimab
and etesevimab monoclonal antibodies (previously authorized for pediatric
patients 12 years of age and older weighing at least 40 kilograms, or about 88
pounds), to additionally authorize bamlanivimab and etesivimab administered
together for the...
The World Health Organization (WHO)
says early evidence suggests the omicron variant may be spreading faster than
the highly transmissible delta variant but brings with it less severe
coronavirus disease though it’s too early to make firm conclusions. Omicron Now in 57 Countries, Could Have Major Impact on Pandemic, Says
WHO.· New
corona...
Sotrovimab has been approved for patients with mild-to-moderate
COVID-19 who are at high risk of developing severe disease.The Medicines and Healthcare
products Regulatory Agency (MHRA) has approved the monoclonal antibody
treatment Sotrovimab (Xevudy; GSK and Vir Biotechnology) for people with
mild-to-moderate COVID-19 and at least one risk fa...
Vitamin D deficiency is one of
the most prevalent micronutrient deficiencies in the world. It has emerged as a
public health problem in many developing countries of the world including Bangladesh.
Over a billion people worldwide are vitamin D deficient. The worldwide
prevalence of vitamin D deficiency is 30-50% among children and even higher in...
A new research report published
by the Centers for Disease Control and Prevention (CDC) has found that wearing
a tight-fitting surgical mask, or doubling up on masks (wearing a cloth mask
over a medical/surgical mask), can significantly reduce COVID-19 transmission
and slow the spread of new, more contagious strains of COVID-19 .Universal maski...
AZD7442 is a combination of two
long-acting antibodies (LAABs) - Tixagevimab and Cilgavimab - derived from B-cells donated by convalescent patients after SARS-CoV-2 virus.The AstraZeneca drug AZD7442, has
been undergoing final stage clinical trials to assess its safety and efficacy. AstraZeneca’s
antibody treatment has been shown to be highly ef...
A nationwide Spanish
cross-sectional study was conducted. Study included patients with cutaneous
reactions within 21 days of any dose of the approved vaccines at the time
of the study.Published in the British Journal of Dermatology
Evaluation of 405 cutaneous reactions after
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) va...
